Nuwellis, Inc. (NUWE) AI Stock Analysis
NUWE AI stock analysis summary
AI ResearchNuwellis, Inc. is a medical device firm focused on ultrafiltration therapy systems for fluid overload. The company reported TTM revenue of $9.0M with an operating margin of -160.9%. Over the past year, its stock has declined 99.5%, leaving the company with a market capitalization of $2.0M.
- Market cap
- $2.0M
- Revenue (TTM)
- $9.0M
- P/E
- 0.0x
- 1Y return
- -99.5% S&P 500 16.8%
- Avg. target
- $11.00 1900.0% vs last close
Bull case
- Revenue for the latest quarter ended June 30, 2026, grew 14.1% year-over-year.
- The balance sheet maintains net cash of $3.7M with total debt limited to $200,000 as of June 30, 2026.
- The mean analyst price target of $11.00 stands 1900.0% above the last closing price of $0.55.
Bear case
- The stock has dropped 99.5% over the past year and trades 98.2% below its 200-day moving average.
- The company produced free cash flow of -$10.9M in FY2025 and has negative shareholders' equity of -$2.1M.
- Share count has expanded by 181100.0% over the trailing 5-year period.
What Nuwellis does
Nuwellis, Inc. is a medical device company specializing in the development, manufacturing, and global distribution of products for ultrafiltration therapy. The company's flagship offerings, the Aquadex FlexFlow and Aquadex SmartFlow systems, treat patients suffering from fluid overload who have not responded adequately to diuretic therapy. Headquartered in Eden Prairie, Minnesota, Nuwellis markets directly to hospitals and clinics across the United States. Internationally, it sells through independent specialty distributors across Europe, Asia, and the Middle East, including Austria, Brazil, India, Israel, and the United Kingdom.
Growth and profitability
Nuwellis generated annual revenue of $7.9M in FY2021, which peaked at $8.9M in FY2023 before decreasing to $8.7M in FY2024 and $8.3M in FY2025. Over the 5-year period from FY2020 to FY2025, revenue grew at a CAGR of 2.1%. Gross margin was 62.0% in FY2025, down from 66.7% in FY2024. Operating margin remained negative throughout, coming in at -134.3% in FY2025 alongside a net income of -$17.5M. In the latest quarter ended June 30, 2026, quarterly revenue grew 14.1% year-over-year, while quarterly earnings declined 99.2%.
Balance sheet and cash flow
As of June 30, 2026, Nuwellis held $3.9M in cash and short-term investments against total debt of $200,000, resulting in net cash of $3.7M. The current ratio stood at 1.97, while shareholders' equity was -$2.1M on total assets of $9.1M. Operating cash flow in FY2025 was -$10.8M, leading to free cash flow of -$10.9M after capital expenditures of $90,000. Over the past five years, the company's share count increased by 181100.0%.
Valuation and performance
At a share price of $0.55, Nuwellis has a market cap of $2.0M and an enterprise value of -$1.0M. Its price-to-sales ratio is 0.2x and its price-to-book ratio is 0.2x, compared to a median price-to-sales ratio of 4.1x for its US-listed Healthcare peers. Its trailing P/E is 0.0x versus the peer median of 24.6x. Over the past year, NUWE fell 99.5%, compared to a 16.8% gain for the S&P 500 (SPY). Over five years, the stock dropped 100.0% while SPY rose 83.0%.
What analysts expect
The mean analyst price target for NUWE is $11.00, representing a 1900.0% premium over its last close of $0.55. For the current fiscal year ending December 31, 2026, the EPS estimate is -$2.29 and the revenue estimate is $17.8M. For the next fiscal year, 1 analyst estimates EPS of -$0.63 and revenue growth of 12.0%. Nuwellis has beaten EPS estimates in 2 of the last 4 quarters, and its next earnings date is November 11, 2026.
Key risks and what to watch
- Shareholders' equity was -$2.1M as of June 30, 2026, indicating negative net worth.
- Cash burn remains significant, with operating cash flow at -$10.8M in FY2025 against $3.9M in cash.
- The 5-year share count change of 181100.0% highlights ongoing share dilution risk.
- Annual net losses continued with -$17.5M reported for FY2025 and a TTM profit margin of -125.6%.
AI-generated research summary. Written with AI from Quotelinks data as of October 16, 2026 and checked so every figure matches that data. For information only, not investment advice. Disclaimer
About this NUWE AI stock analysis
This page is an AI-written research summary of Nuwellis, Inc. (NUWE). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.
Related: NUWE income statement, NUWE balance sheet, NUWE key metrics, NUWE analyst forecast, NUWE chart. See the NUWE stock overview for the latest quote and news.
NUWE AI stock analysis FAQ
What products does Nuwellis develop?
Nuwellis develops and markets the Aquadex FlexFlow and Aquadex SmartFlow systems. These ultrafiltration therapy products treat patients experiencing fluid overload who have not responded adequately to diuretic therapy.
Does Nuwellis pay a dividend?
No, Nuwellis does not pay a dividend. The company directs its capital toward operations, recording FY2025 capital expenditures of $90,000.
What is Nuwellis' cash and debt position?
As of June 30, 2026, Nuwellis had $3.9M in cash and short-term investments and $200,000 in total debt, giving it a net cash balance of $3.7M.
What are analysts projecting for Nuwellis?
Analysts have a mean price target of $11.00 for the stock. For FY2026, the consensus EPS estimate is -$2.29 on estimated revenue of $17.8M.